Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Trends in Cardiovascular Medicine , 33 (3), 159166
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
Tier 1 drugs (generic or preferred brand) carry the lowest copay, often $10$25 per month
This product is not recommended for children below 18 years old and pregnant or breastfeeding women
A study by Xu et al
US$ 21.44
US$ 24.18
US$ 22.75
